Carnitine Levels Decrease during Oxaliplatin Infusion: A Pilot Study.

IF 1.7 4区 医学 Q3 ONCOLOGY
Chemotherapy Pub Date : 2025-05-24 DOI:10.1159/000546614
Lianne P W van Geffen, Floortje Mols, Veerle C M Geurts, Gerard Vreugdenhil
{"title":"Carnitine Levels Decrease during Oxaliplatin Infusion: A Pilot Study.","authors":"Lianne P W van Geffen, Floortje Mols, Veerle C M Geurts, Gerard Vreugdenhil","doi":"10.1159/000546614","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of chemotherapy. Low carnitine levels might negatively affect the development of CIPN. However, little is known of the course of carnitine levels during and directly after chemotherapy administration. Intervention studies using carnitine to prevent CIPN were contradictory, possibly due to different timing and route of carnitine supplementation. Better understanding of carnitine courses might improve future studies. This study aimed to investigate whether oxaliplatin-based chemotherapy administration affects blood and urinary levels of carnitine. We hypothesized that oxaliplatin increases renal excretion of carnitine, thereby causing a carnitine deficiency, which might contribute to the development of CIPN.</p><p><strong>Methods: </strong>Ten patients, starting their first cycle of oxaliplatin-based chemotherapy, were enrolled in this observational pilot study. Blood and urinary samples were taken before, during and after infusion of oxaliplatin. Primary endpoints were changes in plasma and urinary concentrations of free carnitine and carnitine esters during administration of oxaliplatin-based chemotherapy.</p><p><strong>Results: </strong>This study showed a significant decrease of both free carnitine and carnitine esters in plasma 2 h after the start of infusion of oxaliplatin-based chemotherapy. Moreover, a non-significant increase in urine carnitine concentration was seen during the chemotherapy infusion.</p><p><strong>Conclusion: </strong>The altered plasma and urinary concentrations of carnitine support our hypothesis that oxaliplatin causes increased renal excretion of carnitine, thereby lowering blood-carnitine levels and increasing urinary carnitine levels. With continued loss of carnitine over several chemotherapy cycles, this may result in the development of carnitine deficiency, which could contribute to the development of CIPN. These preliminary results provide a basis for hypothesis generation; larger longitudinal studies are required to confirm these findings and to determine the clinical relevance.</p>","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.7000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187101/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546614","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of chemotherapy. Low carnitine levels might negatively affect the development of CIPN. However, little is known of the course of carnitine levels during and directly after chemotherapy administration. Intervention studies using carnitine to prevent CIPN were contradictory, possibly due to different timing and route of carnitine supplementation. Better understanding of carnitine courses might improve future studies. This study aimed to investigate whether oxaliplatin-based chemotherapy administration affects blood and urinary levels of carnitine. We hypothesized that oxaliplatin increases renal excretion of carnitine, thereby causing a carnitine deficiency, which might contribute to the development of CIPN.

Methods: Ten patients, starting their first cycle of oxaliplatin-based chemotherapy, were enrolled in this observational pilot study. Blood and urinary samples were taken before, during and after infusion of oxaliplatin. Primary endpoints were changes in plasma and urinary concentrations of free carnitine and carnitine esters during administration of oxaliplatin-based chemotherapy.

Results: This study showed a significant decrease of both free carnitine and carnitine esters in plasma 2 h after the start of infusion of oxaliplatin-based chemotherapy. Moreover, a non-significant increase in urine carnitine concentration was seen during the chemotherapy infusion.

Conclusion: The altered plasma and urinary concentrations of carnitine support our hypothesis that oxaliplatin causes increased renal excretion of carnitine, thereby lowering blood-carnitine levels and increasing urinary carnitine levels. With continued loss of carnitine over several chemotherapy cycles, this may result in the development of carnitine deficiency, which could contribute to the development of CIPN. These preliminary results provide a basis for hypothesis generation; larger longitudinal studies are required to confirm these findings and to determine the clinical relevance.

奥沙利铂输注期间肉碱水平降低;一项初步研究。
目的:化疗引起的周围神经病变(CIPN)是化疗常见的剂量限制性副作用。低肉碱水平可能对CIPN的发展产生负面影响。然而,人们对化疗期间和化疗后肉碱水平的变化过程知之甚少。使用肉毒碱预防CIPN的干预研究存在矛盾,可能是由于补充肉毒碱的时间和途径不同。更好地了解肉碱的过程可能会改善未来的研究。本研究旨在探讨奥沙利铂为基础的化疗是否会影响血液和尿液中的肉碱水平。我们假设奥沙利铂增加了肉碱的肾脏排泄,从而导致肉碱缺乏,这可能有助于CIPN的发展。方法:10例患者,开始他们的第一个周期奥沙利铂为基础的化疗,登记在这个观察性试点研究。在输注奥沙利铂之前、期间和之后分别采集血液和尿液样本。主要终点是奥沙利铂化疗期间血浆和尿液游离肉碱和肉碱酯浓度的变化。结果:本研究显示奥沙利铂类化疗开始后2小时血浆游离肉碱和肉碱酯均显著降低。此外,化疗输注期间尿肉碱浓度无显著增加。结论:血浆和尿中肉毒碱浓度的改变支持了我们的假设,即奥沙利铂导致肉毒碱肾脏排泄增加,从而降低血中肉毒碱水平,增加尿中肉毒碱水平。随着几个化疗周期中肉碱的持续损失,这可能导致肉碱缺乏症的发展,这可能导致CIPN的发展。这些初步结果为假设生成提供了基础;需要更大规模的纵向研究来证实这些发现并确定临床相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Chemotherapy
Chemotherapy 医学-药学
CiteScore
5.80
自引率
0.00%
发文量
34
审稿时长
6-12 weeks
期刊介绍: This journal publishes original research articles and state-of-the-art reviews on all aspects of antimicrobial and antitumor chemotherapy. The results of experimental and clinical investigations into the microbiological and pharmacologic properties of antibacterial, antiviral and antitumor compounds are major topics of publication. Papers selected for the journal offer data concerning the efficacy, toxicology, and interactions of new drugs in single or combined applications. Studies designed to determine the pharmacokinetic and pharmacodynamics properties of similar preparations and comparing their efficacy are also included. Special emphasis is given to the development of drug-resistance, an increasing problem worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信